{"id":"NCT00957047","sponsor":"Bial - Portela C S.A.","briefTitle":"Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy","officialTitle":"Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2006-08","completion":"2008-01","firstPosted":"2009-08-12","resultsPosted":"2013-08-05","lastUpdate":"2025-03-25"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Epilepsy"],"interventions":[{"type":"DRUG","name":"eslicarbazepine acetate","otherNames":["Zebinix"]},{"type":"DRUG","name":"placebo","otherNames":["Sugar pill"]},{"type":"DRUG","name":"ESL - Part II","otherNames":["Eslicarbazepine acetate (ESL), BIA 2-093"]}],"arms":[{"label":"ESL 400 mg once daily","type":"EXPERIMENTAL"},{"label":"ESL 800 mg once daily","type":"EXPERIMENTAL"},{"label":"ESL 1200 mg once daily","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"ESL - Part II","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who complete Part I may enter a 1-year open-label extension.","primaryOutcome":{"measure":"PART I - Seizure Frequency","timeFrame":"12-week maintenance period","effectByArm":[{"arm":"ESL 1200 mg Once Daily","deltaMin":7,"sd":null},{"arm":"ESL 400 mg Once Daily","deltaMin":8.7,"sd":null},{"arm":"ESL 800 mg Once Daily","deltaMin":7.1,"sd":null},{"arm":"Placebo","deltaMin":9.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":1,"countries":["Portugal"]},"refs":{"pmids":["33338829"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Dizziness","Somnolence","Headache","Diplopia","Coordination abnormal"]}}